公开(公告)号：EP3597647A1

公开(公告)日：2020-01-22

申请号：EP18768432.9

申请日：2018-03-16

申请人： The Kitasato Institute ,  BF Agro Co., Ltd.

发明人： OMURA, Satoshi ,  TAKAHASHI, Yoko ,  NAKASHIMA, Takuji ,  MATSUO, Hirotaka ,  NONAKA, Kenichi ,  SAKATO, Hisako

IPC分类号： C07D407/04 ,  A61K31/352 ,  A61P1/02 ,  A61P1/04 ,  A61P7/00 ,  A61P9/00 ,  A61P11/00 ,  A61P11/04 ,  A61P11/08 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/08 ,  A61P17/00 ,  A61P17/02 ,  A61P17/18 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P39/06

摘要： It is known that foods containing a carbohydrate, e.g., starch, in a large amount produce acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., asparagine, with a reducing sugar. The purpose of the present invention is to provide a novel compound which is effective in inhibiting such foods from yielding acrylamide when treated at a high temperature. Specifically, the present invention provides a compound represented by General Formula (I).

公开(公告)号：EP1160330B1

公开(公告)日：2006-08-09

申请号：EP99973760.4

申请日：1999-03-08

申请人： THE KITASATO INSTITUTE

发明人： OMURA, Satoshi ,  TOMODA, Hiroshi ,  TAKAHASHI, Yoko

IPC分类号： C12P13/00 ,  C12N1/20 ,  C07F15/02 ,  C12P9/00 ,  A61K31/295 ,  C12R1/465

CPC分类号： C12P13/008 ,  C07F15/025 ,  C12P9/00 ,  C12R1/465

摘要： Novel substances WK-5344A and WK-5344B having an effect of inhibiting cholesteryl ester transfer protein; and a process for producing the same which comprises culturing a microorganism belonging to the genus Streptomyces and being capable of producing the substances WK-5344A and WK-5344B in a medium, thus accumulating the substances WK-5344A and WK-5344B in the culture and collecting the substances WK-5344A and WK-5344B therefrom. Because of showing a potent inhibitory activity on cholesteryl ester transfer protein, these substances are useful in preventing and treating human diseases induced by the accumulation of cholesterol.

公开(公告)号：EP1160330A1

公开(公告)日：2001-12-05

申请号：EP99973760.4

申请日：1999-03-08

申请人： THE KITASATO INSTITUTE

发明人： OMURA, Satoshi ,  TOMODA, Hiroshi ,  TAKAHASHI, Yoko

IPC分类号： C12P13/00 ,  C12N1/20

CPC分类号： C12P13/008 ,  C07F15/025 ,  C12P9/00 ,  C12R1/465

摘要： The present invention relates to novel substance having inhibitory action on cholesteryl ester transfer protein, WK-5344A substance and WK-5344B substance, and process for production thereof. A microorganism belonging to genus Streptomyces having ability to produce WK-5344A substance and WK-5344B substance is cultured in a medium, and the WK-5344A substance and the WK-5344B substance are accumulated in the medium, then the WK-5344A substance and the WK-5344B substance are isolated from the said medium. Since the present substance shows significant inhibitory action on cholesteryl ester transfer protein, the substance is effective for prevention and treatment of diseases caused by accumulation of cholesterol in human.

摘要翻译： 本发明涉及对胆固醇酯转移蛋白，WK-5344A物质和WK-5344B物质具有抑制作用的新物质及其生产方法。 将具有产生WK-5344A物质和WK-5344B物质的链霉菌属的微生物培养在培养基中，将WK-5344A物质和WK-5344B物质堆积在培养基中，然后将WK-5344A物质和 WK-5344B物质与所述介质分离。 由于本物质对胆固醇酯转移蛋白质具有显着的抑制作用，所以该物质对于预防和治疗由人体中的胆固醇积聚引起的疾病是有效的。

公开(公告)号：EP1714973A1

公开(公告)日：2006-10-25

申请号：EP04709359.6

申请日：2004-02-09

申请人： THE KITASATO INSTITUTE

发明人： OMURA, Satoshi ,  TOMODA, Hiroshi ,  ABE, Akio ,  IWATSUKI, Masato ,  TAKAHASHI, Yoko

IPC分类号： C07K5/062 ,  C12P21/02 ,  C12N1/20 ,  C12R1/465

CPC分类号： C12R1/465 ,  C07K5/1024 ,  C12P17/165

摘要： The present invention is comprised of culturing a microorganism belonging to genus Streptomyces and having ability to produce K01-0509-A1 substance and/or K01-0509-A2 substance in a medium, accumulating K01-0509-A1 substance and/or K01-0509-A2 substance in the cultured medium and isolating K01-0509-A1 substance and/or K01-0509-A2 substance from the cultured mass. The thus obtained substances can be expected as the selective and effective pharmaceuticals for treatment of infection with enteropathogenic gram negative bacteria having type III secretion system.

摘要翻译： 本发明包括培养属于链霉菌属的微生物，并且能够在培养基中产生K01-0509-A1物质和/或K01-0509-A2物质，积累K01-0509-A1物质和/或K01-0509 -A2物质，并从培养物质中分离K01-0509-A1物质和/或K01-0509-A2物质。 可以预期由此获得的物质是用于治疗具有III型分泌系统的肠致病性革兰氏阴性细菌感染的选择性和有效的药物。

公开(公告)号：EP2752416A1

公开(公告)日：2014-07-09

申请号：EP12828060.9

申请日：2012-08-31

申请人： The Kitasato Institute

发明人： OMURA, Satoshi ,  TAKAHASHI, Yoko ,  NAKASHIMA, Takuji ,  OTOGURO, Kazuhiko ,  SHIOMI, Kazuro ,  IWATSUKI, Masato ,  MATSUMOTO, Atsuko

IPC分类号： C07D493/18 ,  A61K31/366 ,  A61P33/00 ,  C12N1/20 ,  C12P1/06 ,  C12R1/01

CPC分类号： C07D493/16 ,  C07D493/18 ,  C12P17/181 ,  C12R1/01

摘要： [Problem]
The present invention addresses the problem of providing an anti-trypanosomal drug having a novel skeleton, in order to solve issues that occur with conventional technologies.
[Solution]
The present invention is based on the discovery of a microbe that produces an anti-trypanosomal drug having a novel skeleton. Specifically, this invention provides: a compound indicated by formula (I) having a trypanosomal inhibitory activity; an analog thereof; a production method therefor; and a Lechevalieria sp. K10-0216 strain that produces said compound.

摘要翻译： 本发明解决提供具有新骨架的抗锥虫药物的问题，以解决常规技术中出现的问题。 [解决方案]本发明是基于产生具有新骨架的抗锥虫药物的微生物的发现。 具体地，本发明提供：具有锥虫体抑制活性的式（I）表示的化合物; 其类似物; 一种生产方法; 和Lechevalieria sp。 产生所述化合物的K10-0216菌株。

公开(公告)号：EP2752416B1

公开(公告)日：2016-03-09

申请号：EP12828060.9

申请日：2012-08-31

申请人： The Kitasato Institute

发明人： OMURA, Satoshi ,  TAKAHASHI, Yoko ,  NAKASHIMA, Takuji ,  OTOGURO, Kazuhiko ,  SHIOMI, Kazuro ,  IWATSUKI, Masato ,  MATSUMOTO, Atsuko

IPC分类号： C07D493/18 ,  A61K31/366 ,  A61P33/00 ,  C12N1/20 ,  C12P1/06 ,  C12P17/18 ,  C07D493/16 ,  C12R1/01

CPC分类号： C07D493/16 ,  C07D493/18 ,  C12P17/181 ,  C12R1/01

公开(公告)号：EP2019147B1

公开(公告)日：2011-05-04

申请号：EP06732665.2

申请日：2006-05-16

申请人： THE KITASATO INSTITUTE

发明人： TOMODA, Hiroshi ,  KIM, Yong-pil ,  HANAKI, Hideaki ,  MATSUMOTO, Atsuko ,  TAKAHASHI, Yoko ,  OMURA, Satoshi

IPC分类号： C12P19/26 ,  C07H11/04 ,  A61K31/7024 ,  A61P31/04

CPC分类号： C07H11/04 ,  C07C323/59 ,  C12P13/02 ,  C12P19/26 ,  C12P19/44 ,  C12R1/465

摘要： K04-0144 substances A, B and C which can be produced by culturing a microorganism exemplified by Streptomyces sp. strain K04-0144 (which is capable of producing K04-0144 substances) in a culture medium and then collecting the substances from the culture medium. The substances have a potent antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and are therefore useful as therapeutic agents for MRSA infection and infectious diseases caused by multidrug-resistant bacteria including β-lactam antibiotic-resistant bacteria. A novel K04-0144 substance D which is also collected from the culture medium can enhance the effect of a β-lactam antibiotic (which has been used as an antibacterial agent) by using it in combination with the β-lactam antibiotic, and is therefore useful as a therapeutic agent for methicillin-resistant Staphylococcus aureus (MRSA) infection and infectious diseases caused by multidrug-resistant bacteria including β-lactam antibiotic-resistant bacteria.

公开(公告)号：EP2019147A1

公开(公告)日：2009-01-28

申请号：EP06732665.2

申请日：2006-05-16

申请人： THE KITASATO INSTITUTE

发明人： TOMODA, Hiroshi ,  KIM, Yong-pil ,  HANAKI, Hideaki ,  MATSUMOTO, Atsuko ,  TAKAHASHI, Yoko ,  OMURA, Satoshi

IPC分类号： C12P19/26 ,  C07H11/04 ,  A61K31/7024 ,  A61P31/04

CPC分类号： C07H11/04 ,  C07C323/59 ,  C12P13/02 ,  C12P19/26 ,  C12P19/44 ,  C12R1/465

摘要： Amicroorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.

摘要翻译： 由属于链霉菌属的菌株K04-0144代表的微生物。 在培养基中培养具有产生K04-0144物质的能力，并且分离出的K04-0144A物质，K04-0144B物质和K04-0144C物质对包括耐甲氧西林金黄色葡萄球菌（MRSA）在内的革兰氏阳性菌具有强的抗菌活性， 因此它们可用作由MRSA引起的感染性疾病的治疗剂以及由包括β-内酰胺抗生素抗性细菌在内的多种药物引起的感染性疾病。 此外，类似地，由于从培养液中分离出的新型K04-0144D物质具有提高作为抗菌剂使用的β-内酰胺抗生素的效果的作用，因此与它们组合使用时，可用作 由耐甲氧西林金黄色葡萄球菌（MRSA）引起的传染病和包括β-内酰胺抗生素耐药细菌在内的多种药物。

公开(公告)号：EP1550726A1

公开(公告)日：2005-07-06

申请号：EP02777832.3

申请日：2002-10-11

申请人： THE KITASATO INSTITUTE

发明人： OMURA, Satoshi ,  TOMODA, Hiroshi ,  TAKAHASHI, Yoko

IPC分类号： C12P17/08 ,  C07D313/00 ,  A61K31/365 ,  A61P31/10 ,  A61P31/04

CPC分类号： C07D313/00 ,  C07D315/00 ,  C12P17/08 ,  C12R1/465

摘要： The present invention relates to effective drugs for mycosis caused by so called fungi such as fungi and yeast. The present invention is comprised of culturing a microorganism belonging to genus Streptomyces and having ability to produce K99-5278A substance, K99-5278B substance and K99-5278C substance in a medium, accumulating K99-5278A substance, K99-5278B substance and K99-5278C substance in the cultured medium and isolating K99-5278A substance, K99-5278B substance and K99-5278C substance from the cultured mass. The thus obtained substances can be expected as a novel antifungal agent.

摘要翻译： 本发明涉及由所谓的真菌如真菌和酵母引起的用于真菌病的有效药物。 本发明包括培养属于链霉菌属的微生物，并且能够在培养基中产生K99-5278A物质，K99-5278B物质和K99-5278C物质，积累K99-5278A物质，K99-5278B物质和K99-5278C物质 培养基中的物质，并从培养物质中分离K99-5278A物质，K99-5278B物质和K99-5278C物质。 由此获得的物质可以被预期为新型抗真菌剂。